𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Randomized double-blind placebo-controlled multicenter evaluation of efficacy and dose finding of midodrine hydrochloride in women with mild to moderate stress urinary incontinence: a phase II study

✍ Scribed by E. H. J. Weil; P. H. A. Eerdmans; G. A. Dijkman; K. Tamussino; J. Feyereisl; M. E. Vierhout; C. Schmidbauer; C. Egarter; D. Kölle; J. E. M. H. Plasman; H. Heidler; B. E. Abbühl; W. Wein

Publisher
Springer
Year
1998
Tongue
English
Weight
756 KB
Volume
9
Category
Article
ISSN
0937-3462

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A multicentre, randomized, double-blind,
A multicentre, randomized, double-blind, placebo-controlled study to evaluate the efficacy, tolerability and safety of two doses of metrifonate in patients with mild-to-moderate Alzheimer's disease: the MALT study
✍ Bruno Dubois; Ian McKeith; Jean-Marc Orgogozo; Owen Collins; Didier Meulien 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 139 KB 👁 3 views

Background. Metrifonate is a long-lasting acetylcholinesterase inhibitor being developed for the symptomatic treatment of Alzheimer's disease (AD). Objectives. This study compared the ecacy, tolerability and safety of two doses of metrifonate in patients with mild-to-moderate AD, over a 26-week tre

Efficacy and safety of four doses of lum
Efficacy and safety of four doses of lumiracoxib versus diclofenac in patients with knee or hip primary osteoarthritis: A phase II, four-week, multicenter, randomized, double-blind, placebo-controlled trial
✍ Schnitzer, Thomas J. ;Beier, Jannie ;Geusens, Piet ;Hasler, Paul ;Patel, Sanjay 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 128 KB 👁 3 views

## Abstract ## Objective To compare the efficacy and tolerability of the novel cyclooxygenase 2‐selective inhibitor lumiracoxib with placebo and diclofenac in osteoarthritis (OA). ## Methods Adults (n = 583) with knee or hip OA were randomized to receive for 4 weeks lumiracoxib 50, 100, or 200 m

Febuxostat, a novel nonpurine selective
Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: A twenty-eight–day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout
✍ Michael A. Becker; H. Ralph Schumacher Jr.; Robert L. Wortmann; Patricia A. MacD 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 168 KB 👁 3 views

## Abstract ## Objective Gout affects ∼1–2% of the American population. Current options for treating hyperuricemia in chronic gout are limited. The purpose of this study was to assess the safety and efficacy of febuxostat, a nonpurine selective inhibitor of xanthine oxidase, in establishing normal

Phase I, double-blind, randomized, place
Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of NI-0401 (a fully human anti-CD3 monoclonal antibody) in patients with moderate to severe active Crohn's disease
✍ C. Janneke van der Woude; Pieter Stokkers; Ad A. van Bodegraven; Gert Van Assche 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 274 KB 👁 2 views

Background: NI-0401 is a fully human monoclonal antibody, which binds to the CD3 subunit of the T-cell receptor, causing modulation of T-cell activity. We investigated the safety and the ability to modulate the TCR-CD3 complex of NI-0401 in patients with active Crohn's disease (CD). Methods: A doub